Spike Protein News and Research

RSS

Scientists study immune response to COVID-19 in patients with different levels of disease severity

Researchers from Skoltech, U.S. companies VirIntel and Argentys Informatics, and two Russian Academy of Sciences institutes have studied the immune response to COVID-19 in patients with different levels of disease severity.

8 Oct 2021

Israeli Pfizer COVID vaccine/myocarditis study, 136 cases out of 5 million

A new study, published in the New England Journal of Medicine, aimed to present clinical, epidemiological, and follow-up findings of myocarditis cases diagnosed in temporal proximity to COVID-19 vaccination and explore the possibility of a causal relationship between the two.

7 Oct 2021

non-RBD mutation in SARS-CoV-2 variants enhances resistance to neutralizing antibodies

Researchers from Ohio State University have been investigating mutations in the rest of the spike protein, particularly the Q677H mutation.

7 Oct 2021

SARS-CoV-2 evolution promoted by long-term infection in patient with B cell depletion

A new study published on the medRxiv* preprint server focused on a patient with a persistent symptomatic viral infection for over a year. Researchers amplified sub-genomic transcripts for the E gene (sgE) using nasopharyngeal samples of the patient infected with SARS-CoV-2 over the course of 335 days.

6 Oct 2021

Study shows new antibody resistant variants can emerge in patients treated with monoclonal antibodies

A new study, published on the medRxiv* preprint server, suggested that selective pressures induced by the administration of monoclonal antibodies (Bamlanivimab) may require increased genomic surveillance to identify and control the spread of therapy-induced variants.

6 Oct 2021

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

A new study posted to the medRxiv* server and led by Dr. Mattia D'Agostino, Dr. Eleonora Pavoni and Dr. Alice Romagnoli from the Polytechnic University of Marche in Ancona (Italy), a gFET biosensor that uses angiotensin-converting enzyme 2 (ACE2) as a bioreceptor has been put forth as a viable solution.

6 Oct 2021

Durability of immunity to SARS-CoV-2 reinfection

The current study used data on the durability of immunity among evolutionarily close coronavirus relatives of SARS-CoV-2 to estimate times to reinfection.

6 Oct 2021

Study shows strong protective effect of IgG3 antibodies in SARS-CoV-2 infection

Researchers published a study on the expression and functional analyses of a neutralizing mAb with identical variable domains but different constant HCs, representing IgG1-4.

6 Oct 2021

Study shows lower SARS-CoV-2 infection rates in smokers

Coronavirus disease 2019 (COVID-19) primarily infects the lungs, later spreading through the bloodstream. The worst prognoses are mostly seen in ‘at-risk’ groups, such as the immunocompromised, elderly, or those suffering from respiratory conditions.

6 Oct 2021

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Researchers in the United States have shown that a compound currently used to treat cystinosis exhibits broad antiviral activity against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

Researchers in the United States and China have developed plasmid DNA immunogens that induce effective antibody responses in mice against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

Researchers from the US recently characterized the scale and specificity of SARS-CoV-2 spike-reactive antibodies from 23 participants who received SARS-CoV-2 mRNA vaccines and 10 acutely infected health care workers. They found that primary mRNA vaccination and infection elicited S1- and S2-reactive antibodies, while secondary mRNA vaccination elicited mostly S1 antibodies.

4 Oct 2021

Fully vaccinated people with prior SARS-CoV-2 infection have more memory B cells, study shows

A new study by University of Minnesota Medical School researchers is revealing that some people who received an mRNA vaccination for COVID-19 have greater immune responses compared to others.

4 Oct 2021

Study looks at immunosuppressants and COVID vaccine efficacy

Researchers investigate the effects of five established immunosuppressant medications following COVID-19 vaccination.

4 Oct 2021

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

A recent study assesses the serological and cellular responses to Pfizer’s BNT162b2 mRNA vaccine in people aged 80-96 years.

4 Oct 2021

Prevalence of adaptive and prolonged infections’ mutations in receptor-binding domain of SARS-CoV-2 spike protein

A new study used the available nucleotide sequence data on the NCBI COVID-19 database and estimated the global prevalence of adaptive and prolonged infections' mutations in the RBD of the S protein.

4 Oct 2021

Difficulties of stability and storage of mRNA COVID-19 vaccines

Two researchers have collaborated to review the difficulties faced in storing and transporting these vaccines in a manner that will keep them stable.

4 Oct 2021

Using a new public antibody to understand SARS-CoV-2 neutralization

SARS-CoV-2 infects host cells by binding to the angiotensin convertase 2 receptor (ACE2) on the cell surface through its trimeric spike (S) protein. SARS-CoV enters host human cells through endosomes, while SARS-CoV-2 enters through the cell surface and endosomes. The present study published in the journal “Cell Reports” aimed to understand the mechanisms of SARS-CoV-2 antibody neutralization to facilitate the development of therapeutic interventions for COVID-19.

4 Oct 2021

Immune response to SARS-CoV-2 variants of concern after natural infection or vaccination

A recent review paper published in the MDPI's journal Viruses highlights how available vaccines may be effective in protecting individuals against severe forms of coronavirus disease 2019 (COVID-19), but the protection against infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its transmission to others may be reduced – with consequences for community protection and herd immunity.

3 Oct 2021

Spike Protein News and Research

Scientists study immune response to COVID-19 in patients with different levels of disease severity

Israeli Pfizer COVID vaccine/myocarditis study, 136 cases out of 5 million

non-RBD mutation in SARS-CoV-2 variants enhances resistance to neutralizing antibodies

SARS-CoV-2 evolution promoted by long-term infection in patient with B cell depletion

Study shows new antibody resistant variants can emerge in patients treated with monoclonal antibodies

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

Durability of immunity to SARS-CoV-2 reinfection

Study shows strong protective effect of IgG3 antibodies in SARS-CoV-2 infection

Study shows lower SARS-CoV-2 infection rates in smokers

Cysteamine inhibits SARS-CoV-2 variants of concern in vitro

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to natural infection

Fully vaccinated people with prior SARS-CoV-2 infection have more memory B cells, study shows

Study looks at immunosuppressants and COVID vaccine efficacy

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

Prevalence of adaptive and prolonged infections’ mutations in receptor-binding domain of SARS-CoV-2 spike protein

Difficulties of stability and storage of mRNA COVID-19 vaccines

Using a new public antibody to understand SARS-CoV-2 neutralization

Immune response to SARS-CoV-2 variants of concern after natural infection or vaccination

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News